PD-L1 Request the Test

GET THE FULL PICTURE
Request the test


Setting your patients on the right treatment path

Using biomarker testing to understand a patient’s PD-L1 status and how each person’s cancer is different, will help tailor their treatment selection.1

Order a PD-L1 test for your patients to give the multi-disciplinary team all of the information they need to ensure a more targeted treatment pathway, as early as possible.

The importance of testing for PD-L1

Biomarkers can provide a more complete understanding of a patient’s cancer.1

Testing for PD-L1 expression is widely recommended across a range of cancer types.1-3

Bioassays can be used to detect PD-L1 expression on tumour cells4. The information provided by testing plays an important part of achieving a full and complete diagnosis for your patients, with a strong history of predicting success.1,3,4

For more information on PD-L1 testing please contact either Dr Paul O’Sullivan or Olivia Fenwick:

Dr Paul O’Sullivan
Mobile:027 569 5497
Olivia Fenwick
Mobile:027 807 8777

Patient selection

TEST

Test

for PD-L1 expression at diagnosis

IDENTIFY

Identify

appropriate patients with tumours that express PD-L1

TREAT

Treat

with the appropriate treatment plan

Key trial data with KEYTRUDA

Find out more about KEYTRUDA, a targeted immunotherapy designed to block the interaction between the PD-1 receptor and its ligands, PD-L1 and PD-L2.

Keytruda KN-189

Accessing KEYTRUDA

If KEYTRUDA is a potential treatment for your patient and they don’t qualify for PHARMAC funding, there are other avenues to consider.

References: 1. PD-L1 in Cancer: ESMO Biomarker Factsheet. Available at: https://oncologypro.esmo.org/Education-Library/Fact- sheets-on-Biomarkers/PD-L1-in-Cancer#eztoc1489281_0_0_4 [Accessed September 2018]. 2. NCCN Clinical Practice Guidelines. Version 4.2018 NSCLC. Available at: https://www.nccn.org/professionals/physician_gls/default.aspx#site [Accessed September 2018]. 3. Ionescu DN, et al. Harmonization of PD-L1 testing in oncology: a Canadian pathology perspective. Curr Oncol. 2018 Jun; 25(3): e209–e216. 4. Liu D, Wang S, Bindeman W. Clinical applications of PD-L1 bioassays for cancer immunotherapy. J Hematol Oncol. 2017;10(1):110. 7

ONCO-1250168-0048


Online enrolment and ordering for the Patient Programme
is under development.
To register a patient or request resupply please contact dpoc.nz@merck.com

KEYTRUDA (pembrolizumab) 50mg powder for infusion

Before prescribing KEYTRUDA, read the data sheet for information on dosage, contraindications, precautions, interactions and adverse effects available at www.medsafe.govt.nz or on request from Merck Sharp & Dohme (New Zealand) Limited. Prescription Only Medicine Indication: As monotherapy for the treatment of unresectable or metastatic melanoma in adults. In combination with pemetrexed and platinum chemotherapy for first-line treatment of metastatic non-squamous NSCLC, with no EGFR or ALK genomic tumour aberrations. As monotherapy for first-line treatment of patients with metastatic NSCLC whose tumours express PD-L1 ≥50% tumour proportion score (TPS) on a validated test, with no EGFR or ALK genomic tumour aberrations. As monotherapy for the treatment of patients with advanced NSCLC with a PD-L1 TPS level ≥1% and who have received platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumour aberrations should have received prior therapy for these aberrations prior to receiving KEYTRUDA. As monotherapy for refractory/ relapsed classical Hodgkin Lymphoma (cHL). As monotherapy for patients with locally advanced/ metastatic urothelial carcinoma who are not eligible for cisplatin-containing chemotherapy, or who have received platinum-containing chemotherapy. As monotherapy for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) with disease progression on or after platinum-containing chemotherapy. See full data sheet. Contraindications: None. Precautions: Immune-mediated adverse reactions, including pneumonitis, colitis, hepatitis, nephritis, hypophysitis, type 1 diabetes mellitus, hyperthyroidism, hypothyroidism, thyroiditis, uveitis, myositis, Guillain-Barre syndrome, pancreatitis, encephalitis, sarcoidosis, myasthenic syndrome, severe skin reactions (including Stevens-Johnson syndrome and toxic epidermal necrolysis), and severe infusion reactions including hypersensitivity and anaphylaxis. Severe and fatal cases of immune-mediated adverse reactions have occurred. Increased mortality when in combination with dexamethasone and a thalidomide analogue in multiple myeloma (not indicated). Immune-mediated adverse reactions affecting more than one body system can occur simultaneously. For management of immune-mediated adverse events, see full data sheet. Limited information in patients with active infection and patients with on-going adverse reaction to ipilimumab – use caution. Acute graft-versus-host-disease (potentially fatal) in patients with history of allogeneic HSCT. Post-marketing: solid organ transplant rejection and myocarditis. See full data sheet for further information. Interactions: None expected. Avoid corticosteroids or immunosuppressants prior to treatment. Side effects: Clinical trials (treatment-related only): nasopharyngitis, anaemia, neutropenia, hypothyroidism, decreased appetite, dizziness, headache, cough, dyspnea, abdominal pain, constipation, diarrhea, nausea, vomiting, erythema, pruritus, rash, vitiligo, arthralgia, back pain, myalgia, pain in extremity, asthenia, chills, fatigue, oedema peripheral, pyrexia, colitis, hepatitis, hyperthyroidism, hypophysitis, nephritis, pneumonitis, type 1 diabetes mellitus, adrenal insufficiency, autoimmune hepatitis, alopecia, upper respiratory tract infection. Dosage and administration: The recommended dose of KEYTRUDA is 200 mg for previously untreated NSCLC, HNSCC, cHL, and urothelial carcinoma, and 2 mg/kg or 200 mg for melanoma or previously treated NSCLC (administered as an intravenous infusion over 30 minutes every 3 weeks). KEYTRUDA should be administered first when given in combination with pemetrexed and platinum chemotherapy. Treat with KEYTRUDA until disease progression or unacceptable toxicity. Atypical responses (i.e. an initial transient increase in tumour size or small new lesions followed by shrinkage) have been observed. Clinically stable patients (i.e. asymptomatic and not requiring urgent intervention) with initial evidence of progression can remain on treatment until confirmed. See full data sheet for further information, including details on PD-L1 testing. KEYTRUDA is a funded medicine for melanoma patients– restrictions apply. KEYTRUDA is a private purchase medicine for NSCLC, HNSCC, cHL and urothelial carcinoma patients. Based on data sheet prepared 17 July 2018.

Copyright © 2018 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. All rights reserved. Copyright © 2018 Merck Sharp & Dohme (New Zealand) Limited. Level 3, 123 Carlton Gore Road, Newmarket, Auckland. All rights reserved.
ONCO-1230760-0024 DA1827MW First Issued October 2015 Updated: October 2018
This site is intended for New Zealand Healthcare Professionals

Copyright   Privacy   Terms of Use